This is a working overview of IGF-1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2 to 8 °C | Refrigerated, protected from light |
| Appearance | White to off-white powder | Lyophilized cake in a single-use vial |
| Solubility | Soluble in water | Yields a clear solution after reconstitution |
| Identity method | Electrospray mass spectrometry | Confirms the expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main peak against related substances |
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Essential medicines, as defined by the World Health Organization (WHO), are "those drugs that satisfy the health care needs of the majority of the population; they should therefore be available at all times in adequate amounts and in appropriate dosage forms, at a price the community can afford." Recent studies have found that most of the medicines on the WHO essential medicines list, outside of the field of HIV drugs, are not patented in the developing world, and that lack of widespread access to these medicines arise from issues fundamental to economic development – lack of infrastructure and poverty. Médecins Sans Frontières also runs a Campaign for Access to Essential Medicines campaign, which includes advocacy for greater resources to be devoted to currently untreatable diseases that primarily occur in the developing world. The Access to Medicine Index tracks how well pharmaceutical companies make their products available in the developing world. World Trade Organization negotiations in the 1990s, including the TRIPS Agreement and the Doha Declaration, have centered on issues at the intersection of international trade in pharmaceuticals and intellectual property rights, with developed world nations seeking strong intellectual property rights to protect investments made to develop new drugs, and developing world nations seeking to promote their generic pharmaceuticals industries and their ability to make medicine available to their people via compulsory licenses.
Susan Weintraub is an American scientist. She is a professor at the University of Texas Health Science Center at San Antonio (UTHSCSA). She received a BS in chemistry from the University of Pennsylvania in 1967, MS in chemistry from Trinity University in 1970 and a PhD in biochemistry from UTHSCSA in 1979. She was the president of the American Society for Mass Spectrometry for the period of 2012-2014. In 2017 she was named a Fellow of the American Association for the Advancement of Science (AAAS), and Fellow of the American Society for Mass Spectrometry in 2025. She is an associate editor of the Journal of Proteome Research. Her research focuses on biomedical mass spectrometry where she used mass spectrometry in the early 1970s for quantitative analysis of brain neurochemicals. She has been director of the mass spectrometry core resource at UTHSCSA since 1979.
On 1 May 1989, the American Physical Society held a session on cold fusion in Baltimore, including many reports of experiments that failed to produce evidence of cold fusion. At the end of the session, eight of the nine leading speakers stated that they considered the initial Fleischmann and Pons claim dead, with the ninth, Johann Rafelski, abstaining. Steven E. Koonin of Caltech called the Utah report a result of "the incompetence and delusion of Pons and Fleischmann," which was met with a standing ovation. Douglas R. O. Morrison, a physicist representing CERN, was the first to call the episode an example of pathological science. On 4 May, due to all this new criticism, the meetings with various representatives from Washington were cancelled. From 8 May, only the A&M tritium results kept cold fusion afloat. In July and November 1989, Nature published papers critical of cold fusion claims. Negative results were also published in several other scientific journals including Science, Physical Review Letters, and Physical Review C (nuclear physics). In August 1989, in spite of this trend, the state of Utah invested $4.5 million to create the National Cold Fusion Institute. The United States Department of Energy organized a special panel to review cold fusion theory and research. The panel issued its report in November 1989, concluding that results as of that date did not present convincing evidence that useful sources of energy would result from the phenomena attributed to cold fusion.
The superconducting transition temperature has been found to peak at an optimal doping value (p=0.16) and an optimal number of layers in each superconducting block, typically n=3. The undoped "parent" or "mother" compounds are Mott insulators with long-range antiferromagnetic order at sufficiently low temperatures. Single band models are generally considered to be enough to describe the electronic properties. Cuprate superconductors usually feature copper oxides in both the oxidation states 3+ and 2+. For example, YBa2Cu3O7 is described as Y3+(Ba2+)2(Cu3+)(Cu2+)2(O2−)7. The copper 2+ and 3+ ions tend to arrange themselves in a checkerboard pattern, a phenomenon known as charge ordering. All superconducting cuprates are layered materials having a complex structure described as a superlattice of superconducting CuO2 layers separated by spacer layers, where the misfit strain between different layers and dopants in the spacers induce a complex heterogeneity that in the superstripes scenario is intrinsic for high-temperature superconductivity.
The Open Insulin Project is a community of researchers and advocates working to develop an open-source protocol for producing insulin that is affordable, has transparent pricing, and is community-owned.
Sources: en.wikipedia.org
==== Animal ==== Progesterone is produced in high amounts in the ovaries (by the corpus luteum) from the onset of puberty to menopause. The hormone is produced in smaller amounts by the adrenal glands after the onset of adrenarche in both males and females. To a lesser extent, progesterone is produced in nervous tissue, especially in the brain, and also in adipose tissue (fat). During human pregnancy, progesterone is produced in increasingly high amounts by the ovaries and placenta. At first, the source is the corpus luteum that has been "rescued" by the presence of human chorionic gonadotropin (hCG) from the conceptus. However, after the eighth week, production of progesterone shifts to the placenta which uses maternal cholesterol as the initial substrate, and most of the produced progesterone enters the maternal circulation, but some is picked up by the fetal circulation and used as substrate for fetal corticosteroids. At term, the placenta produces about 250 mg progesterone per day. An additional animal source of progesterone is milk products. After consumption of milk products the level of bioavailable progesterone goes up.
Mayonnaise and Hollandaise sauces – these are oil-in-water emulsions stabilized with egg yolk lecithin, or with other types of food additives, such as sodium stearoyl lactylate Homogenized milk – an emulsion of milk fat in water, with milk proteins as the emulsifier Vinaigrette – an emulsion of vegetable oil in vinegar, if this is prepared using only oil and vinegar (i.e., without an emulsifier), an unstable emulsion results Water-in-oil emulsions are less common in food, but still exist:
The critical structural element of all glycoproteins is having oligosaccharides bonded covalently to a protein. There are 10 common monosaccharides in mammalian glycans including: glucose (Glc), fucose (Fuc), xylose (Xyl), mannose (Man), galactose (Gal), N-acetylglucosamine (GlcNAc), glucuronic acid (GlcA), iduronic acid (IdoA), N-acetylgalactosamine (GalNAc), sialic acid, and 5-N-acetylneuraminic acid (Neu5Ac). These glycans link themselves to specific areas of the protein amino acid chain. The two most common linkages in glycoproteins are N-linked and O-linked glycoproteins. An N-linked glycoprotein has glycan bonds to the nitrogen containing an asparagine amino acid within the protein sequence. An O-linked glycoprotein has the sugar is bonded to an oxygen atom of a serine or threonine amino acid in the protein. Glycoprotein size and composition can vary largely, with carbohydrate composition ranges from 1% to 70% of the total mass of the glycoprotein. Within the cell, they appear in the blood, the extracellular matrix, or on the outer surface of the plasma membrane, and make up a large portion of the proteins secreted by eukaryotic cells. They are very broad in their applications and can function as a variety of chemicals from antibodies to hormones.
=== Detector === A Faraday cup measures the ion current hitting a metal cup, and is sometimes used for high-current secondary-ion signals. With an electron multiplier, an impact of a single ion starts off an electron cascade, resulting in a pulse of 108 electrons, which is recorded directly. A microchannel plate detector is similar to an electron multiplier, with lower amplification factor but with the advantage of laterally-resolved detection. Usually it is combined with a fluorescent screen, and signals are recorded either with a CCD-camera or with a fluorescence detector.
=== Cleaning === • surface (suction cleaning by vacuum) • wet (cleaning with water or water plus detergent) • dry (cleaning with organic solvents) • spotting (treating of localized stains with wet or dry-cleaning solvents) Wet, dry, and spotting treatments should always be conducted by professionals. Vacuum maintenance of materials in open exhibit, textiles being returned to storage, and newly accessioned textiles before they are displayed or stored is best practice. Aqueous cleaning of archaeological textiles achieves "relaxation of folds and removal of surface dirt without causing further weakening of the object.”
Sources: en.wikipedia.org
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.
Mass spectrometry gives the molecular weight, and mapping after digestion gives sequence coverage. Reversed-phase chromatography then supplies a purity profile.
Different groups report purity with different methods and thresholds, and full validation data are seldom published. Direct comparison of activity across batches therefore stays uncertain.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.